PMWC 2020 Silicon Valley
Luminary & Pioneer Awards

Date & Agenda

When: January 21th, 2020 at 6:00-8:00pm

Agenda: TBA

Where: UCSF Mission Bay – Genentech Hall

Suggested dress: Cocktail attire

Venue

UCSF Mission Bay – Genentech Hall
1675 Owens Street, San Francisco, Ca 94158

Genentech Hall

600 16th St, SF, CA
Get Directions

Community Garage

1625 Owens St, SF, CA
Get Directions

Third St. Garage

1630 3rd St, SF, CA
Get Directions

Parking & Directions

PARKING
Paid parking is available onsite at Mission Bay Conference Center Parking Garage. There are two parking lots located on opposites sides of the building. See Parking Garage info here.

UCSF SHUTTLES
There are multiple UCSF shuttles that provide access to the Mission Bay Conference Center (Green, Red, Gold, Blue, Gray, Lilac). The most frequently used are the Green Shuttle from Caltrain at 4th & King and the Red Shuttle from 16th Street BART. View the shuttle map and schedules here.

BART
Take BART to the 16th Street stop. Exit the station to the left of the turnstiles. Walk to the right towards the sidewalk of 16th street. The UCSF Shuttle stops in front of the Burger King Restaurant. Take the Red Shuttle to Mission Bay Community Center (William J. Rutter Center). (The shuttle itself is not colored red, the signage on the shuttle says “Red”). Shuttle arrives every 15 minutes, starting at 6:15AM with the last one at 8:05PM

MUNI
T-Line – Third Street light rail stops at the Mission Bay UCSF Campus (The UCSF/Mission Bay Stop is between the 4th Street & King and 3rd Street & 20th Stops shown in the T-Line Schedule). For train schedules, visit www.sfmuni.com.

AIRPORT
San Francisco International Airport (SFO) – 25 minutes
Oakland International Airport (OAK) – 45 minutes

DRIVING DIRECTIONS
FROM THE NORTH BAY/GOLDEN GATE BRIDGE

After crossing the Golden Gate Bridge, drive east on 101 (Doyle Drive) towards downtown.
Exit at Marina Boulevard and follow Marina Boulevard past Fort Mason.
Turn left onto Bay Street.
Turn right onto the Embarcadero.
After passing under the Bay Bridge, the Embarcadero will become King Street.
Turn left onto 3rd Street just past AT&T Baseball Park.
Cross 3rd street (Lefty O’Doul Bridge) and continue south on 3rd Street.
Turn right on 16th Street.
Turn right onto Owens Street.
Turn right into the parking garage.

FROM THE SOUTH BAY/SAN FRANCISCO AIRPORT: 101 NORTH

Exit onto Vermont Street.
Turn right onto 16th Street and continue for 0.6 miles.
Cross the railroad tracks that are under the I-280 overpass.
Turn left onto Owens Street.
Turn right into the parking garage.
FROM THE SOUTH BAY/SAN FRANCISCO AIRPORT: 280 NORTH
Exit at Mariposa Street and turn left.
Turn right on Mississippi Street and go two blocks.
Turn right on 16th Street.
Turn left onto Owens Street.
Turn right into the parking garage.

FROM THE EAST BAY/BAY BRIDGE

After crossing the Bay Bridge, exit at Fifth Street and turn left onto Harrison.
Go one block, then turn left on 6th Street.
Turn right on Brannan.
Turn left on 7th and go straight until 16th Street.
Turn left on 16th Street.
Turn left onto Owens Street.
Turn right into the parking garage.

Luminary Pioneer Company Competition

Past Luminary Award Recipients

Mary V. Relling

2018- Michigan

Pioneer and advocate for pharmacogenomic personalized medicine

Jeffrey I. Gordon

2018- Duke

Pioneered the study of gut microbial ecology and evolution and today addresses the global challenges of obesity and undernutrition

Eric Topol

2018- Michigan

Pioneered genetics and genomics in cardiovascular medicine and led the era of wireless medicine

Susan A. Murphy

2018- Michigan

Developing innovative data science methods to improve patient care through mobile health in chronic disease

Emmanuelle Charpentier

2018

Pioneered the CRISPR-CAS9 Genome Editing Technology

Jennifer Doudna

2017

Pioneered the Groundbreaking Crispr-Cas9 Genome Editing Technology

Edward F. Chang

2017

Pioneer in Human Brain Circuit Mapping to Advance Precision Neuropathology

James Allison

2017

Pioneered Cancer Immunotherapy Through Discovery of the Immune Checkpoint Blockade

Roger Perlmutter

2016

Expedited Development of Groundbreaking Therapies

Laura Esserman

2016

Breast Cancer Treatment Paradigm Shifter

Ron Davis

2015

Developed R-loop Technique of Electron Microscopy

Jay Flatley

2014

Established Illumina as the leader in sequence technology

Janet Woodcock

2013

FDA Director, fast-tracked targeted drugs through FDA approval

Brian Druker

2012

Co-inventor, blockbuster drug, Gleevec

George Church

2011

Contributions to the sequencing of genomes and interpreting such data; In Neuroscience he established a “functional connectome”

Lee Hood

2010

Inventions included the automated DNA sequencer and a tool for synthesizing DNA

Past Pioneer Award Recipients

Michael Boehnke

2018- Michigan

Pioneered large-scale studies identifying genetic risk in diabetes and Bipolar Disorder

Ronald Levy

2018

Pioneered the concept of antibodies being used as personalized anticancer drugs

Sir John Bell

2018

Leading Genetic and Genomic Research Initiatives that Enable Precision Medicine in the UK and Globally

Alan Ashworth

2018

Co-discovered the BRCA2 gene mutation and made discoveries leading to PARP inhibition in breast and other cancers

Steve Quake

2017

Steve Quake has pioneered innovative approaches to biological measurement

Irv Weissman

2016

Pioneer in Regenerative Medicine & Cancer Stem Cells

Ralph Snyderman

2016

Widely recognized as “Father of Personalized Medicine”

Craig Venter

2015

1st Draft Human Gen., 1st Complete Diploid Human Gen., and 1st Synth. Bact. Cell

Dennis Lo

2015

Discovered That An Unborn Fetus Releases Fetal DNA Into Maternal Plasma

Jonathan K.C. Knowles

2015 – UK

Personalized Medicine Leader in both Academia and the Pharmaceutical Industry

Yuet Wain Kan

2014

The first to establish that a single DNA mutation could lead to a human disease, and the first to diagnose a human disease by using DNA

Michael Hayden

2014 – Israel

Developer, First Predictive Test for Huntington’s Disease

Kim Popovits

2013 – Israel

Launched both earliest genetically-targeted therapy and molecular diagnostic assay

Most Promising Company Award

The PMWC Most Promising Company Competition has accompanied PMWC since 2009 with the goal to assist “rising star” startups in Diagnostics, Therapeutics, and Health Tech to increase their visibility, provide them with a platform to present to a group of leading investors, as well as to potential clients and partners so they can succeed on their path forward.

Abreos Biosciences

Abreos Biosciences is a precision medicine company in San Diego, CA developing laboratory-based and near-patient tests for precision dosing of biologic drugs. Abreos has cultivated a diverse portfolio of Veritope™ tests that allow for direct monitoring of blood concentrations of monoclonal antibody drugs (novel or biosimilar). Website: abreos.com

Immusoft

Immusoft’s mission is re-program patient cells into miniature drug factories that engraft and survive for decades in the body. Website: immusoft.com

Two Pore Guys

Two Pore Guys

Two Pore Guys created a solid-state nanopore-based diagnostic testing platform that can detect nucleic acids, proteins and other analytes with comparable performance of lab equipment, in a glucometer-style system. Website: twoporeguys.com

Gritstone Oncology

Gritstone Oncology

Every patient’s tumor is molecularly unique – Gritstone Oncology deploys a proprietary tumor antigen prediction model based upon patient tumor sequencing/mass spectrometry to deliver antigens as personalized therapeutic vaccine alongside checkpoint inhibitors. Website: gritstoneoncology.com

healthmyne

HEALTHMYNE

HealthMyne is an imaging informatics company dedicated to transforming patient care by enabling image data mining within the clinical workflow. Built on an FDA-cleared diagnostic platform, HealthMyne tools will increase radiologist efficiency by automating both data capture and structured reports. Website: healthmyne.com

insilico

INSILICO MEDICINE

Insilico Medicine, Inc. is a bioinformatics company located at the Emerging Technology Centers at the Johns Hopkins University Eastern campus in Baltimore. It utilizes advances in genomics, big data analysis and deep learning for in silico drug discovery and drug repurposing for aging and age-related diseases. Website: insilicomedicine.com

accel-diag

ACCEL DIAGNOSTICS

AccelDx’s technology enables patients and healthcare providers to perform lab-quality medical diagnostic tests at any time and any place. The patented pScreen™ platform technology employs a single-use blood test the size of a credit card in tandem with a smartphone application to quickly detect disease-specific biomarker levels. Website: acceldx.com

t2-biosystems

T2 BIOSYSTEMS

T2 Biosystems is an in vitro diagnostics company that has developed an innovative and proprietary technology platform that is designed to offer a rapid, sensitive and simple alternative to existing diagnostic methodologies. Their new class of clinical diagnostics powered by T2MR is the world’s first direct detection technology that delivers superior sensitivity at unmatched speed to guide more effective clinical decision-making. IPO, Aug. 2014. Website: t2biosystems.com

elminda

ELMINDA

ElMindA has developed the BNA™ technology platform, which for the first time allows high resolution visualization and evaluation of the complex neuro-physiological interconnections of the human brain at work, capturing information on the composition, connectivity, synchronization and operation of brain networks. Website: elminda.com

horizon

HORIZON DISCOVERY

Horizon Discovery Limited has developed a translational genomics platform and drug discovery toolbox that enables the development of new therapies targeted at the genetic features that drive an individual’s cancer. IPO, March 2014. Website: horizondiscovery.com

quanta-life

QUANTALIFE

QuantaLife provides advanced genetic analysis systems for research. QuantaLife has commercialized the Droplet Digital™ (ddPCR) system, the most accurate genetic analysis platform available today. The system is the first cost-effective, high-resolution platform available for the validation of next-generation sequencing discoveries. With the ddPCR system, researchers can explore complex genetic landscapes in high-definition, discover new disease associations, and define a new category of improved molecular diagnostic tests. Acquired by Bio-Rad, October 2011. Website: bio-rad.com

Applied-I1

APPLIED IMMUNE TECHNOLOGIES

Applied Immune Technologies’ (AIT) core technology platforms encompass the identification and validation of novel MHC-based targets, as well as development of therapeutic Human Recombinant T-Cell Receptor-Like (TCRL) antibodies with the unique ability to bind with these intracellular peptide/MHC complexes with the specificity of cytotoxic T-cell killer cells. Acquired by Adicet Bio, January 2016. Website: tcrl.co.il

BHL

BOSTON HEART LAB

Boston Heart Diagnostics is a heart health management company providing integrated diagnostic and patient management solutions that are advancing cardiovascular disease risk assessment, monitoring and treatment. The Company’s goal is to predict, prevent, manage and reverse cardiovascular disease by improving patient assessment and management. Acquired by Eurofins Scientific, December 2014. Website: bostonheartdiagnostics.com

Testimonials

Get Exclusive Access to the Top PMWC Talks

To receive the most comprehensive news and updates from the field of precision medicine, subscribe to the newsletter here.

Bonus for suscribing, you will get the access code for the top 3 talk videos from January's Precision Medicine World Conference.

You have successfully subscribed, you can access the talks here.